Glenmark Pharmaceuticals Ltd share price declined by 3.13% to Rs 2191.05. The Company's net profit saw a strong growth of 60.24% to Rs 482.83 crore, while revenue from operations improved marginally 4.56% to Rs 3931.73 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 23.86 lakh crore, gaining 6%. It has inched up 2.79% over last one week and surged by 15.59% in last one month while the market capitalization of Glenmark Pharmaceuticals Ltd has improved by 1.83% and 7.16% in the same period respectively. Profit before tax (PBT) of Glenmark Pharmaceuticals Ltd stood at Rs 643.39 crore in Q2 FY26, expanding by 573.14% year-on-year, and rallying 65.92% quarter-on-quarter. EBITDA came in at Rs 739 crore, surging by 33.38% YoY and jumping 28.86% sequentially. Total expenses grew marginally by 7.32% to Rs 3386.86 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 601.07 crore, falling by 17.80% YoY, while employee benefits expense was at Rs 934.7 crore, easing 5.33% YoY. For the TTM ended FY26, revenue from operations improved 12.98% to Rs 13145.84 crore, while net profit witnessed a sharp fall of 157.19% to Rs 1047.14 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 25845% to Rs 2237.66 crore, and PBT surged 3733.45% to Rs 1399.21 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 827.6 crore in FY26, as against Rs 265.44 crore in FY25. Glenmark Pharmaceuticals Ltd gained 1.66% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 4.36% during the same period.
